Alaunos Therapeutics Inc. (TCRT) Next Earnings Date & Expected ±12.5% Move

Per the Roarable RQD rating, TCRT scores 36 out of 100, earning a D- grade and the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the Fundamental Cash Engine scores 9/20 (ROIC of -35%, FCF yield of 0%), indicating the business is not currently generating returns on capital or free cash. Whale/13F Flow scores 8/20, reflecting institutional accumulation and options positioning that is weak relative to the maximum. Insider Conviction scores 3/20, the lowest pillar, tied to SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 8/20 with a beta of 1.0 and sector sensitivity noted. Forensic Balance Sheet scores 8/20, supported by an Altman Z-Score of 2.5, a Piotroski F-Score of 3/9, and a Debt/Equity ratio of 0.5. For a prospective investor, the rating signals a stock with negative operating economics, limited insider confidence, and a balance sheet flagged as vulnerable. Any valuation discussion must start from the absence of positive earnings, cash flow, and reported earnings per share; upside arguments depend on factors outside the reported fundamentals.

Alaunos Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M across the periods provided, and gross margin is 0%. Per the profile, the company's market capitalization is recorded as $0.0B, which conflicts with the $7.8M market cap shown in market data.

Per the SEC financials, the company reported no revenue and operating losses in each period shown, with an operating margin of -60% and net margin of -60% in market data. ROIC is -35%. The Piotroski F-Score is 3/9 and the Altman Z-Score is 2.5, per the Roarable RQD rating. Debt/Equity is 0.5, and reported cash is $1.4M for FY 2025.

Per the recent news wire, several headlines describe a sharp share-price move, including a report that the stock traded 200% higher on a Tuesday and a headline citing triple-digit gains on an acquisition and funding. Another headline reports completion of a Velaris acquisition with shares surging. A Nasdaq equity-compliance regain is reported, with listing to continue. Yahoo Finance UK published a seasonal returns chart. A Stock Titan report notes that director Jaime Vieser received 22,669 shares in lieu of board fees. Risk watch items include the -11.27% change in the latest price and the volatility implied by the 52-week range of $0.72 to $4.5. Per the Butterfly Supply-Chain Graph, the proprietary liquidity signal is labeled LIQUIDITY_TAILWIND with a macro tailwind score of 96/100 and severity of 94, direction BULLISH. The signal reports a True Net Liquidity Index of $5,745.73B, a 6.00x Net Liquidity beta, and an r of -0.21, and it describes TCRT as liquidity-sensitive. Treat this as a model output rather than a fundamental finding.

• What products or clinical programs drive the company, and what is the revenue pathway given zero reported revenue?
• How does the reported $0.0B market capitalization in the profile reconcile with the $7.8M market cap in market data?
• What were the terms and dilution impact of the acquisition and funding referenced in the news wire?
• What is the cash runway given FY 2025 cash of $1.4M and FCF of $-3.0M, and does the company have committed financing?
• What drove the reported 200% and triple-digit intraday moves, and were they accompanied by elevated share issuance?